{filename}

Publications

Categories

Filter by Topics

ADCC Gene Alteration ALK Angiogenesis Anti-TNF Alpha Therapy Apoptosis Asthma Autocrine Signaling Autoimmune Disorder Biofluid Biology of neoplasia Biomarker Analysis Biomarker Validation Biomarkers Bladder Brain Breast Cancer CDKN2A mutation Cells Cerebrospinal Fluid Childhood Atopic Dermatitis Chronic Obstructive Pulmonary Disease Circulating miRNAs cMET Colorectal cancer Comparison study Core Needle Biopsy Custom mRNA Cytokines Developmental Immunotherapy Developmental Therapeutics Diabetes Differential Gene Expression Analysis DLBCL Drug Response Drug Safety Drug Targets Drug-induced Liver Injury Efficacy EGFR Muatations EMT Encephalophy Epstein-Barr ERBB3 Esophageal Cancer Exosomes Extracellular Vesicles Fabry Disease FFPE FGF Ligand Trap FGFR Fibrous Tumors Follicular lymphoma Gene Expression Profiling Gene Fusions Genetic Polymorphism Genitourinary cancer Glioblastoma Tumors Head and Neck Cancer Heart HER2 Histone Deacetylase Inhibitors HLA-E HPV HTG EdgeSeq ALKPlus Assay EU HTG EdgeSeq Custom Assays HTG EdgeSeq DLBCL Cell of Origin Assay HTG EdgeSeq DLBCL Cell of Origin Assay EU HTG EdgeSeq EGFR KRAS and BRAF Mutation Assay HTG EdgeSeq Immuno-Oncology Assay HTG EdgeSeq Lung Fusion Assay HTG EdgeSeq miRNA Whole Transcriptome Assay HTG EdgeSeq Mouse mRNA Tumor Response Panel HTG EdgeSeq Oncology Biomarker Panel HTG EdgeSeq PATH Assay HTG EdgeSeq Precision Immuno-Oncology Panel HTG EdgeSeq System HTG EdgeSeq System Oncology Biomarker Panel Immune Checkpoint Inhibitors Immune Related Genes Immune Response Immune Tolerance Immune-related Colitis Immuno-Oncology Immunotherapy Inflammation Juvenile Arthritis Kidney Liposarcoma Liquid Biopsy Liver Lung Lupus Lymph Node Metastasis Lymphoma Mechanism of Action Melanoma Mesothelioma MET Microenvironment miRNA Molecular Characterization Mouse mRNA custom mTOR pathway Multiple Myeloma Muscle Mutations MYC NAFLD Nash and Fibrosis Natural Killer Cells Neoantigens Neuroendocrine Tumor Neurologic non-Hodgkin Lymphoma Novel Therapeutic Targets NTRK1 Oesophageal Adenocarcinoma Oncology Oral Cancer Osteoclast Ovarian cancer Pancreas Paralysis Parkinson's Disease Pathogenesis Pathway Analysis PBMCs PCA Cell Lines PIK3CA mutation Placenta Plasma Platform Comparison Predictive Modeling Programmed cell death protein 1 Progression free-survival Prostate qNPA qPCR Radioimmunotherapy Rearrangements Response rate RET Reveal Rheumatoid Arthritis Risk Score ROS1 safety Sarcoma Serum Signaling Inhibitors Signatures Sinonasal Carcinoma SPECS Lung Consortium Squamous cell carcinoma Sub-typing Surveillance Survival Outcomes Survival plots Synovial Fluid Therapeutic Response Therapeutic targets TMB Toxicity TP53 mutation Translational Medicine Transplantation Treatment Outcome Treatment Stratification Treatment Targets Tumor Biology Tumor Heterogeneity Tumor Immunobiology Tumor infiltrating lymphocytes Urothelial carcinoma VEGFR Xenograft Tissue

Evaluation of a novel microRNA Whole Transcriptome Assay

MicroRNAs (miRNAs) are short, ~22nt RNA sequences that are believed to modulate gene transcription and downstream cell behavior. There are several platforms used for quantitation of low-abundance miRNA targets found in circulating human bodily fluids. These were evaluated in a miRNA quality control (miRQC) study (Nature Methods 11, 809-815, 2014), which compared 12 commercially available platforms for analysis of miRNA expression to identify their strengths and weaknesses, and help guide informed selection of a quantitative microRNA gene expression platform for particular study goals.

In this webcast, the performance of the HTG EdgeSeq miRNA Whole Transcriptome Assay (WTA) is evaluated using the samples and methods from the miRQC study. This is a new technology that enables users to measure the expression of 2,083 human miRNA transcripts using next-generation sequencing.

In this webcast you will

  • Learn about the objectives and strategy for genomic platform comparison studies described by the MicroArray Quality Control (MAQC) consortium.
  • Understand performance metrics used in platform comparison studies.
  • Discover key analytic outcomes through a case study utilizing the HTG EdgeSeq miRNA Whole Transcriptome Assay.
     

Speaker

Bonnie LaFleur

Speaker Biography

Dr. LaFleur is a quantitative scientist with extensive experience in scientific research.  She has developed regulatory strategies for immuno-oncology companion diagnostic FDA-approved products and has been a key contributor to multiple in vitro diagnostic device submissions.  Dr. LaFleur has published over 90 peer-reviewed publications focusing on genomic biomarkers

Return To List